Wu, J and Zhu, Z and Yu, Q and Ding, C, Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials, Expert Opinion on Investigational Drugs, 28, (12) pp. 1113-1123. ISSN 1354-3784 (2019) [Refereed Article]
Copyright 2019 Informa UK Limited, trading as Taylor & Francis Group
Areas covered: The key findings from phase I and II clinical trials that have investigated the use of novel TKIs in the treatment of RA are discussed. We examined the literature published between January 2014 to January 2019 using electronic databases including PubMed, Web of Science, Medline, Embase, and Google Scholar. Additional information about phase I and II trials on the ClinicalTrial.gov website up to January 2019 was also retrieved.
Expert opinion: JAK inhibitors are promising drugs with sound efficacy and acceptable safety and may be beneficial to patients who do not respond to DMARDs and biologicals. The response rates among RA patients to TKIs are diverse; genetic and environmental factors may be involved in the varying responses which are closely related to the pathogenesis of RA. Future studies may reveal the underlying mechanisms of resistance and non-response.
|Item Type:||Refereed Article|
|Keywords:||Brutonís tyrosine kinases, Janus kinase, rheumatoid arthritis, disease-modifying anti-rheumatic drugs, spleen tyrosine kinases, tyrosine kinase inhibitor|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Rheumatology and arthritis|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Ding, C (Professor Chang-Hai Ding)|
|Web of Science® Times Cited:||2|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page